| Quantification of indoor air pollution from using cookstoves and estimation of its health effects on adult women in northwest Bangladesh Z Chowdhury, LT Le, A Al Masud, KC Chang, M Alauddin, M Hossain, ... Aerosol and air quality research 12 (4), 463-475, 2012 | 95 | 2012 |
| Addition of navitoclax to ongoing ruxolitinib therapy for patients with myelofibrosis with progression or suboptimal response: phase II safety and efficacy CN Harrison, JS Garcia, TCP Somervaille, JM Foran, S Verstovsek, ... Journal of Clinical Oncology 40 (15), 1671-1680, 2022 | 89 | 2022 |
| Measurement and modeling of indoor air pollution in rural households with multiple stove interventions in Yunnan, China Z Chowdhury, L Campanella, C Gray, A Al Masud, J Marter-Kenyon, ... Atmospheric Environment 67, 161-169, 2013 | 76 | 2013 |
| A comparison of multiple testing adjustment methods with block-correlation positively-dependent tests JR Stevens, A Al Masud, A Suyundikov Plos one 12 (4), e0176124, 2017 | 75 | 2017 |
| Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t (11; 14) NJ Bahlis, R Baz, SJ Harrison, H Quach, SJ Ho, AJ Vangsted, T Plesner, ... Journal of Clinical Oncology 39 (32), 3602-3612, 2021 | 53 | 2021 |
| Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma LJ Costa, FE Davies, GP Monohan, T Kovacsovics, N Burwick, ... Blood Advances 5 (19), 3748-3759, 2021 | 48 | 2021 |
| Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy S Ma, JF Seymour, DM Brander, TJ Kipps, MY Choi, MA Anderson, ... Blood, The Journal of the American Society of Hematology 138 (10), 836-846, 2021 | 35 | 2021 |
| Variable selection for mixture and promotion time cure rate models A Masud, W Tu, Z Yu Statistical methods in medical research 27 (7), 2185-2199, 2018 | 27 | 2018 |
| Final overall survival results from BELLINI, a phase 3 study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma S Kumar, SJ Harrison, M Cavo, J de la Rubia, R Popat, CJ Gasparetto, ... Blood 138, 84, 2021 | 21 | 2021 |
| Durability of responses on continuous therapy and following drug cessation with venetoclax and rituximab: long-term follow-up analysis of a phase 1b study in patients with … DM Brander, JF Seymour, TJ Kipps, S Ma, MA Anderson, MY Choi, ... Blood 134, 3036, 2019 | 16 | 2019 |
| MPN-038: navitoclax in combination with ruxolitinib in patients with primary or secondary myelofibrosis: a phase 2 study C Harrison, JS Garcia, R Mesa, T Somervaille, EK Ritchie, RS Komrokji, ... Clinical Lymphoma Myeloma and Leukemia 20, S325, 2020 | 15 | 2020 |
| Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone,+/-bortezomib, in patients with relapsed/refractory multiple myeloma. JL Kaufman, RC Baz, SJ Harrison, H Quach, SJ Ho, AJ Vangsted, ... Journal of Clinical Oncology 38 (15_suppl), 8511-8511, 2020 | 14 | 2020 |
| A phase 3, double-blind, placebo-controlled, randomized study evaluating navitoclax in combination with ruxolitinib in patients with myelofibrosis (TRANSFORM-1) J Potluri, J Harb, AA Masud, JE Hutti Blood 136, 4, 2020 | 13 | 2020 |
| Durability of responses on continuous therapy and following drug cessation in deep responders with venetoclax and rituximab DM Brander, JF Seymour, S Ma, MA Anderson, MY Choi, TJ Kipps, ... Blood 132, 183, 2018 | 11 | 2018 |
| Navitoclax and ruxolitinib for patients with myelofibrosis and JAK inhibitor experience: response duration in phase 2 study C Harrison, J Garcia, T Somervaille, JM Foran, S Verstovsek, C Jamieson, ... EHA2021 Virtual Congress, 9-17, 2021 | 7 | 2021 |
| Venetoclax Improves Quality Of Life For Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia T Cochrane, T Chagorova, T Robak, S Yeh, E Nikitin, M Breuleux, ... Congress of the European Hematology Association (EHA) 215726 (PS1438), 2018 | 7 | 2018 |
| Variable selection and nonlinear effect discovery in partially linear mixture cure rate models AA Masud, Z Yu, W Tu Biostatistics & Epidemiology 3 (1), 156-177, 2019 | 5 | 2019 |
| Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy S Handunnetti, MA Anderson, AW Roberts, MS Davids, S Ma, M Boyer, ... EJHaem 2 (2), 266-271, 2021 | 4 | 2021 |
| Long-term follow-up of patients with mantle cell lymphoma treated with venetoclax monotherapy MS Davids, AW Roberts, WG Wierda, K Humphrey, DJ Alter, A Masud, ... Blood 132, 2883, 2018 | 4 | 2018 |
| Debulking eliminates need for hospitalization prior to initiating frontline venetoclax therapy in previously untreated CLL patients: a phase 3b study JP Sharman, D Andorsky, JM Melear, S Manda, BM Anz III, KS Kolibaba, ... Blood 134, 3042, 2019 | 3 | 2019 |
Zohir ChowdhuryAssociate Professor of Environmental Health, Graduate School of Public Health, San Diego State University在 sdsu.edu 的电子邮件经过验证
